Diffuse large B-cell lymphoma complicated by cytokine release syndrome and immune effector cell–associated neurotoxicity on day 355 of epcoritamab therapy: a case report
Journal of Clinical and Experimental Hematopathology · 2026 · 66 (2) · 177-181
DOI: 10.3960/jslrt.26004 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2026. Verfasst von Yasunobu Sekiguchi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
100 mg/body), which resulted in complete remission (CR 1) (Figure 1b). However, the illness recurred in February Year X-4. The patient was subsequently treated with six courses of R-MECP therapy (rituximab 375 mg/m 2 , carboplatin 300 mg/ m 2 , etoposide 70 mg/m 2 , mitoxantrone 8 mg/m 2 , and prednisone 40 mg/m 2 ), which again resulted in CR (CR 2). The illness recurred once more in March Year X-2, and the patient received six courses of PBR therapy (polatuzumab vedotin 1.8 mg/kg, bendamustine 90 mg/m 2 , and rituximab 375 mg/m 2 ), which led to CR 3. The lymphocyte count was 3720/μL immediately before the start of PBR therapy and decreased to 90/μL by its completion. In November Year X-1, the illness recurred again (Figure 1c), and by December, epcoritamab was initiated (following a bendamustine washout period of 15.5
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan.
- Department of Clinical Laboratory Medicine, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan.
- Department of Inspection Engineering, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan.
- Department of Pathology, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan.
- Department of pharmacy, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan.
- Department of Radiation therapy, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan.
Zitieren
APA
Sekiguchi, Y., Arai, K., Hamano, S., Kudo, M., Maseki, N., Iizaki, Y., Kawamura, M., Kobayashi, K., Nishimura, Y., Kanda, H., Takei, D., Abe, T., Hanai, M., Endo, S., Nakayama, T., Shimano, Y., & Kobayashi, H. (2026). Diffuse large B-cell lymphoma complicated by cytokine release syndrome and immune effector cell–associated neurotoxicity on day 355 of epcoritamab therapy: a case report. Journal of Clinical and Experimental Hematopathology, 66(2), 177-181. https://doi.org/10.3960/jslrt.26004
Vancouver
Sekiguchi Y, Arai K, Hamano S, Kudo M, Maseki N, Iizaki Y, et al. Diffuse large B-cell lymphoma complicated by cytokine release syndrome and immune effector cell–associated neurotoxicity on day 355 of epcoritamab therapy: a case report. Journal of Clinical and Experimental Hematopathology. 2026;66(2):177-181. doi:10.3960/jslrt.26004
BibTeX
@article{Sekiguchi2026,
author = {Sekiguchi, Yasunobu and Arai, Kosuke and Hamano, Shizuka and Kudo, Masahisa and Maseki, Nobuo and Iizaki, Yoshie and Kawamura, Machiko and Kobayashi, Kazuhiko and Nishimura, Yu and Kanda, Hiroaki and Takei, Daisuke and Abe, Tomoya and Hanai, Makoto and Endo, Sayaka and Nakayama, Toshiaki and Shimano, Yasumasa and Kobayashi, Hirofumi},
title = {Diffuse large B-cell lymphoma complicated by cytokine release syndrome and immune effector cell–associated neurotoxicity on day 355 of epcoritamab therapy: a case report},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2026},
volume = {66},
number = {2},
pages = {177--181},
doi = {10.3960/jslrt.26004}
}
EUVIMED